Shanghai Chest Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 1957-01-01

Employees: -

Market Cap: -

Website: http://www.shmtppp.com/hospitals/chest

Clinical Trials

mCBCT in Combination With ENB for the Diagnosis of PPNs

Recruiting

Conditions: Peripheral Pulmonary Nodules
Lung Cancer

Interventions: Device: Electromagnetic Navigation Bronchoscopy (superDimension™ Navigation System) and Mobile Cone-Beam CT (Cios Spin)

First Posted Date: 2022-08-26

Last Posted Date: 2023-09-13

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 109

Registration Number: NCT05518669

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Feasibility of Thin Cp-EBUS Scope BF-UC290F for the Diagnosis of PPLs

Not Applicable

Conditions: Peripheral Pulmonary Nodules

Interventions: Device: Linear Ultrasound Bronchoscope BF-UC290F (Olympus)

First Posted Date: 2022-08-23

Last Posted Date: 2022-08-29

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 30

Registration Number: NCT05512533

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

China Lung Cancer Screening (CLUS) Study Version 3.0

Not Applicable

Recruiting

Conditions: Lung Cancer

Interventions: Other: Whole-process management software
Device: LDCT detection

First Posted Date: 2022-08-09

Last Posted Date: 2022-08-09

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 100000

Registration Number: NCT05494021

Locations: 🇨🇳
Shanghai Chest hospital, Shanghai, Shanghai, China

Comparison of Peri-procedural Complications of Intracardiac Echocardiography and Transesophageal Echocardiography in Patients With Atrial Fibrillation

Not Applicable

Conditions: Atrial Fibrillation

Interventions: Device: ICE
Device: TEE

First Posted Date: 2022-07-20

Last Posted Date: 2022-07-20

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 1200

Registration Number: NCT05466266

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

Phase 2

Recruiting

Conditions: Minimal Residual Disease
Anti-angiogenesis
Non-small Cell Lung Cancer
Immunotherapy

Interventions: Drug: sintilimab combined with anlotinib
Drug: sintilimab monotherapy

First Posted Date: 2022-07-15

Last Posted Date: 2022-07-15

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 42

Registration Number: NCT05460195

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, China

CARTO-Finder Guided Ablation Versus Multiscale Entropy Guided Ablation in Persistent Atrial Fibrillation

Not Applicable

Not yet recruiting

Conditions: Persistent Atrial Fibrillation

Interventions: Procedure: CARTO-Finder-guided ablation plus PVI
Procedure: Multiscale entropy-guided ablation plus PVI

First Posted Date: 2022-07-12

Last Posted Date: 2022-07-12

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 200

Registration Number: NCT05454111

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, China

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Dacomitinib+Anlotinib
Drug: Dacomitinib

First Posted Date: 2022-03-09

Last Posted Date: 2023-04-19

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 140

Registration Number: NCT05271916

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Adjunctive Right Atrial Ablation for Persistent Atrial Fibrillation With Right Atrial Enlargement

Completed

Conditions: Persistent Atrial Fibrillation
Right Atrial Enlargement

Interventions: Procedure: Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation + right atrial driver ablation
Procedure: Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation

First Posted Date: 2022-02-07

Last Posted Date: 2022-02-07

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 195

Registration Number: NCT05227586

Locations: 🇨🇳
Mu Qin, Shanghai, China

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

Not Applicable

Not yet recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Anlotinib

First Posted Date: 2022-02-01

Last Posted Date: 2022-02-01

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 30

Registration Number: NCT05218759

SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC

Phase 2

Not yet recruiting

Conditions: NSCLC, Stage III

Interventions: Drug: SHR-1701

First Posted Date: 2022-01-04

Last Posted Date: 2022-01-04

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 19

Registration Number: NCT05177497

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy